A Controversial Shift in Hepatitis B Prevention: Are We Undoing Public Health Success?
The recent decision by the CDC's Advisory Committee on Immunization Practices (ACIP) has sparked a heated debate in the medical community. In a surprising move, ACIP voted to remove the universal birth-dose hepatitis B vaccine recommendation for infants born to HBV-negative mothers. This decision, made on December 5, 2025, marks a significant change in the long-standing approach to hepatitis B prevention.
But why is this a big deal?
In this episode of Liver Lineup, hosts Dr. Nancy Reau and Dr. Kim Brown delve into the potential consequences of this shift. They argue that the ACIP decision contradicts decades of data and progress in reducing HBV prevalence and chronic infection rates. Since the 1990s, the universal birth dose has been a powerful tool in preventing hepatocellular carcinoma, acting as an 'anti-cancer vaccine'.
And here's where it gets controversial...
Dr. Brown, drawing from her transplantation expertise, highlights a stark contrast. Before widespread HBV vaccination, chronic HBV infection was a primary reason for liver transplants. Now, thanks to vaccination and antiviral therapy, HBV-related transplants are rare. However, the new ACIP recommendation may reintroduce preventable infections, a concerning prospect.
The discussion uncovers a critical issue: the assumption of perfect maternal screening and documentation. In reality, HBV screening during pregnancy is often inconsistent, and results may not be shared across systems. This could leave one in five pregnant individuals without a documented HBV test, a significant gap in protection.
Reau and Brown emphasize that early-life exposure, not adult behavior, is the main cause of chronic HBV infection. Household transmission and contact with unscreened adults are still significant risks, even with known maternal status. Delaying vaccination to 2 months provides no safeguard during this critical period.
The lifelong impact of early HBV infection is profound. Chronic HBV remains a leading cause of hepatocellular carcinoma, and reactivation during immunosuppression is a risk. Therefore, prevention, not treatment, is key.
Despite ACIP's aim to empower individualized decision-making, Reau and Brown worry about increasing vaccine disparities, undoing progress, and putting infants, especially those in underserved areas, at unnecessary risk.
The episode concludes with a call to action: clinicians should stay informed, discuss delayed vaccination risks with families, and protect the public health gains achieved through universal hepatitis B immunization over three decades.
What's your take on this controversial decision? Do you agree with the hosts' concerns, or do you see a different perspective?
